Upward Trajectory: Capricor Therapeutics Inc (CAPR) Posts a Gaine%, Closing at $6.25

Kevin Freeman

Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.

The closing price of Capricor Therapeutics Inc (NASDAQ: CAPR) was $6.25 for the day, up 1.46% from the previous closing price of $6.16. In other words, the price has increased by $1.46 from its previous closing price. On the day, 1.26 million shares were traded. CAPR stock price reached its highest trading level at $6.54 during the session, while it also had its lowest trading level at $6.0188.

Ratios:

Our analysis of CAPR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.37 and its Current Ratio is at 4.37. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Alliance Global Partners on June 30, 2025, initiated with a Buy rating and assigned the stock a target price of $20.

On June 26, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $21.

On May 20, 2025, Roth Capital started tracking the stock assigning a Buy rating and target price of $31.Roth Capital initiated its Buy rating on May 20, 2025, with a $31 target price.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAPR now has a Market Capitalization of 285731104 and an Enterprise Value of 163974528. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.34 while its Price-to-Book (P/B) ratio in mrq is 2.72. Its current Enterprise Value per Revenue stands at 12.244 whereas that against EBITDA is -2.284.

Stock Price History:

The Beta on a monthly basis for CAPR is 0.62, which has changed by -0.6961595 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, CAPR has reached a high of $22.90, while it has fallen to a 52-week low of $5.68. The 50-Day Moving Average of the stock is -9.67%, while the 200-Day Moving Average is calculated to be -39.49%.

Shares Statistics:

CAPR traded an average of 1.51M shares per day over the past three months and 1025160 shares per day over the past ten days. A total of 45.71M shares are outstanding, with a floating share count of 40.16M. Insiders hold about 12.17% of the company’s shares, while institutions hold 36.48% stake in the company. Shares short for CAPR as of 1759190400 were 11738250 with a Short Ratio of 7.78, compared to 1756425600 on 11491393. Therefore, it implies a Short% of Shares Outstanding of 11738250 and a Short% of Float of 29.209998.

Earnings Estimates

. The current rating of Capricor Therapeutics Inc (CAPR) is the result of assessments by 7.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.28 and low estimates of -$0.61.

Analysts are recommending an EPS of between -$1.85 and -$2.37 for the fiscal current year, implying an average EPS of -$2.14. EPS for the following year is $0.47, with 8.0 analysts recommending between $3.47 and -$2.45.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.